transplant
cell
human
origin
sector
medicin
show
increas
excit
opportun
treatment
diseas
incur
ensur
provis
safe
reliabl
cell
tissu
applic
necessari
regul
procur
process
test
preserv
storag
distribut
cell
destin
applic
human
bodi
function
entrust
tissu
bank
although
one
differenti
nuanc
depend
type
tissu
handl
patient
group
serv
establish
design
meet
requir
tissu
bank
outlin
nation
recommend
depart
health
american
associ
tissu
bank
specif
intern
standard
eg
intern
organ
standard
accredit
appropri
compet
author
direct
although
numer
tissu
bank
europ
accredit
nation
inspect
specif
requir
bank
human
stem
cell
line
address
uk
stem
cell
bank
nibsc
accredit
medic
healthcar
product
regulatori
agenc
pincock
mayor
uk
code
practic
tissu
bank
base
uk
orang
guid
gpmd
uk
blood
transfus
servic
red
book
ukbtsnibsc
stem
cell
bank
must
assur
qualiti
traceabl
safeti
product
aim
particularli
import
avoid
transmiss
diseas
achiev
close
attent
standardis
process
implement
qualiti
control
programm
method
reflect
current
best
practic
qualiti
import
aspect
cell
cultur
good
practic
laboratori
frequent
monitor
cell
line
vital
research
centr
use
cell
cultur
would
mandatori
cultur
intend
clinic
use
cell
therapi
regen
medicin
tissu
bank
aim
screen
process
tissu
seriou
human
pathogen
assur
contamin
introduc
bank
procedur
includ
storag
thu
within
qualiti
assur
programm
establish
one
fundament
pillar
adequ
prepar
introduct
microbiolog
environment
biosafeti
qualiti
assur
programm
obvious
seriou
human
pathogen
present
risk
process
tissu
staff
well
recipi
patient
furthermor
microbiolog
contamin
donor
materi
introduc
manufactur
process
potenti
multipli
process
stage
present
seriou
hazard
recipi
even
overt
pathogen
cell
cultur
process
provid
ideal
condit
growth
mani
organ
includ
virus
use
antibiot
necessarili
protect
microbi
growth
may
mask
presenc
certain
organ
inhibit
elimin
leav
mask
contamin
may
well
infect
futur
recipi
stem
cell
line
four
key
area
microbiolog
control
donor
biolog
materi
includ
preembryo
appropri
screen
carri
avoid
transmiss
infecti
agent
feeder
cell
cell
line
product
biolog
reagent
product
use
cell
cultur
procedur
potenti
sourc
contamin
strict
control
establish
sourc
qualiti
controlenvironment
control
work
condit
laboratori
plan
process
storag
areassafeti
test
regim
stem
cell
bank
review
intend
give
overview
methodolog
use
type
establish
microbiolog
control
cell
line
submit
order
assur
qualiti
avoid
transmiss
infect
main
point
consid
fulli
inform
consent
procedur
technic
criteria
assess
elig
donor
includ
laboratori
test
requir
criteria
accept
cell
except
case
coupl
donat
reproduct
cell
direct
use
ie
exclud
storag
donat
human
cell
assess
approv
one
person
person
clinic
advisor
appropri
experi
use
tissu
clinic
use
also
complet
specif
train
programm
familiaris
bank
procedur
depart
health
addit
diagnost
test
assess
presenc
risk
known
transmiss
diseas
patholog
harm
agent
extens
studi
medic
record
lifestyl
questionnair
carri
human
cell
includ
reproduct
cell
potenti
transmit
infecti
diseas
past
donor
screen
human
immunodefici
viru
hiv
hepat
virus
mainli
b
hbv
c
hcv
us
food
drug
administr
depart
health
test
carri
use
current
avail
protocol
base
detect
donor
antibodi
respons
viral
infect
research
shown
detect
antibodi
exclus
run
risk
sampl
test
taken
antibodyneg
window
period
infect
ie
absenc
reactiv
antibodi
individu
expos
viral
infect
inde
viraem
hitzler
runkel
hcv
hiv
potenti
agent
concern
categori
individu
shown
neg
presenc
reactiv
antibodi
howev
viraem
number
month
seroconvers
schreiber
et
al
stramer
et
al
find
led
introduct
nucleic
acid
amplif
techniqu
polymeras
chain
reaction
pcr
presenc
viru
observ
mean
amplif
sequenc
viral
genom
although
preval
rate
hbv
hcv
hiv
human
cell
lymphotroph
viru
htlv
lower
among
tissu
donor
gener
popul
dodd
et
al
estim
probabl
undetect
viremia
time
tissu
donat
higher
among
tissu
donor
among
firsttim
blood
donor
janssen
et
al
dodd
et
al
addit
nucleic
acid
test
nat
method
screen
tissu
donor
test
deriv
cell
line
reduc
risk
infect
among
recipi
stem
cell
line
zou
et
al
current
regul
requir
donor
screen
includ
test
rang
virus
caus
seriou
human
diseas
known
transmit
blood
tissu
tabl
list
expand
donor
provid
leucocyterich
cell
tissu
includ
htlvi
htlvii
hcv
cytomegaloviru
cmv
consid
cellassoci
virus
addit
virus
hepat
e
also
includ
associatedrisk
group
may
need
consid
note
nation
guidelin
may
vari
spain
determin
hepat
b
surfac
antigen
hbsag
antibodi
hcv
antibodi
cmv
antibodi
toxoplasma
antibodi
heart
transplant
mandatori
also
htlvihtlvii
antibodi
determin
would
made
risk
factor
identifi
donor
consensu
document
although
list
might
expand
even
light
develop
knowledg
technolog
inevit
balanc
drawn
associ
risk
infect
resourc
time
requir
perform
everincreas
list
viru
test
current
donor
screen
nonvir
agent
may
includ
syphili
uk
msbt
inevit
requir
test
transmiss
spongiform
encephalopathi
tse
includ
diseas
cjd
sensit
clinic
valid
assay
becom
avail
us
food
drug
administr
european
medicin
evalu
agenc
food
drug
administr
fda
propos
requir
donor
reproduct
cell
tissu
test
neisseria
gonorrhoea
chlamydia
trachomati
known
transmit
artifici
insemin
screen
sexual
transmit
genitourinari
diseas
could
contamin
reproduct
cell
tissu
recoveri
transmit
recipi
cell
tissu
tabl
known
virus
herpesvirus
herp
simplex
viru
hsv
viru
human
herpesviru
human
polyomavirus
jc
bk
virus
parvoviru
transfus
transmit
viru
ttv
remain
latent
detect
human
earli
childhood
potenti
contamin
cell
normal
healthi
individu
takeuchi
et
al
cassinotti
et
al
garbuglia
et
al
fanci
et
al
arnold
et
al
virus
could
screen
pcr
test
biolog
product
howev
work
involv
establish
clinic
valid
test
underestim
includ
establish
use
appropri
nation
intern
refer
materi
saldanha
virus
ubiquit
may
clinic
impact
presenc
transplant
tissu
cell
major
patient
certain
case
parvoviru
contamin
blood
product
maximum
limit
current
genom
equival
per
dose
accept
use
human
howev
instanc
agent
prove
concern
heart
transplant
patient
transfer
organ
cmvposit
donor
recipi
never
expos
viru
prove
fatal
owe
high
degre
immunosuppress
requir
patient
avoid
reject
accordingli
infecti
agent
consid
potenti
pathogen
risk
balanc
use
contamin
product
establish
includ
consider
recipi
prior
exposur
compet
fight
infect
microbi
agent
mark
variat
geograph
distribut
produc
infecti
epidem
differ
area
recent
us
substanti
increas
incid
diseas
caus
west
nile
viru
center
diseas
control
prevent
case
appear
asymptomat
mani
individu
know
infect
therefor
potenti
risk
cell
tissu
donat
infect
type
viru
virus
multipli
major
human
cell
viru
compromis
biolog
product
noteworthi
viru
one
group
arthropodborn
virus
infect
human
awar
amongst
tissu
coordin
new
outbreak
diseas
new
emerg
diseas
import
safeti
human
transplant
use
tissu
product
recent
outbreak
sever
acut
respiratori
syndrom
sar
viru
human
south
east
asia
clearli
demonstr
potenti
appear
new
seriou
pathogen
mean
screen
donor
tissu
obvious
new
entiti
aris
consid
contamin
risk
factor
donor
record
eg
frequent
intern
travel
vacat
highrisk
area
may
use
first
line
defenc
contamin
donat
furthermor
specif
test
may
requir
may
develop
surveil
initi
case
sar
detect
method
develop
caus
coronaviru
agent
juang
et
al
risk
viral
contamin
donor
may
also
influenc
cell
type
predomin
tissu
origin
may
predispos
certain
type
contamin
approach
may
use
identifi
virus
like
present
exampl
lung
tissu
may
carri
respiratori
pathogen
adenoviru
influenza
viru
respiratori
syncyti
viru
etc
approach
propos
risk
assess
cell
line
doblhoffdi
et
al
frommer
et
al
might
appli
stem
cell
line
clear
use
human
cell
product
remain
quarantin
store
separ
process
liquid
nitrogen
storag
vessel
determin
whether
product
accept
base
result
qualiti
control
screen
test
perform
accredit
laboratori
relev
contamin
tabl
bacteri
contamin
usual
evid
nake
eye
sudden
increas
turbid
colour
chang
cultur
medium
result
chang
ph
cell
cultur
may
surviv
short
time
cell
die
eventu
daili
observ
cultur
ensur
earli
detect
contamin
enabl
appropri
action
taken
soon
first
sign
contamin
becom
appar
avoid
contamin
cultur
moreov
specif
test
detect
bacteria
yeast
fungi
use
part
routin
regular
qualiti
control
screen
procedur
detect
low
level
infect
sampl
cell
cultur
product
may
inocul
either
liquid
eg
trypton
soya
broth
fluid
thioglycol
medium
onto
solid
eg
agar
blood
agar
sabouraud
dextros
agar
malt
extract
agar
growth
media
standard
protocol
test
given
pharmacopoei
standard
european
pharmacopeia
european
pharmacopeia
b
inocul
media
may
incub
differ
temperatur
reflect
condit
human
pathogen
cultur
eg
environment
organ
lower
growth
temperatur
optima
eg
day
microbiolog
cultur
incub
depend
specif
test
standard
use
media
qualiti
control
equip
test
parallel
use
challeng
refer
strain
potenti
contamin
procedur
carri
microbiolog
laboratori
isol
cell
cultur
laboratori
steril
test
capabl
detect
larg
number
bacteri
fungal
speci
membran
filtrat
product
either
open
close
system
prefer
steril
test
methodolog
european
pharmacopeia
filter
prewet
particularli
small
volum
antibiot
test
product
filter
direct
inocul
immers
situ
incub
combin
method
appropri
accept
valid
studi
demonstr
media
capabl
support
growth
wide
rang
microorgan
test
contain
inspect
interv
incub
period
presenc
turbid
liquid
media
characterist
coloni
solid
media
observ
record
identif
microorgan
confirm
use
confirmatori
test
microbi
identif
system
either
manual
convent
procedur
autom
manual
method
offer
advantag
use
analyt
skill
technologist
read
interpret
test
wherea
autom
system
offer
handsoff
approach
allow
technologist
time
duti
system
backbon
accuraci
strength
util
databas
ohara
et
al
detect
mycoplasma
cultur
refer
method
detect
theoret
level
detect
colonyform
unit
cfu
howev
strain
mycoplasma
noncultiv
eg
strain
hyorhini
coloni
observ
agar
plate
speci
exhibit
characterist
fri
egg
appear
cultur
carri
specif
solid
eg
pleuropneumonialik
organ
pplo
agar
plate
pig
serum
agar
plate
liquid
eg
liquid
pplo
medium
pig
serum
agar
broth
media
week
aerob
anaerob
atmospher
includ
intern
neg
control
use
refer
strain
european
pharmacopoeia
test
publish
techniqu
european
pharmacopeia
cultur
media
includ
thallou
acet
inhibit
bacteria
isol
confirm
achiev
pcr
see
hoechst
stain
bind
specif
dna
use
uv
epifluoresc
microscop
fluoresc
nuclei
extranuclear
fluoresc
reveal
small
cocci
filament
correspond
mycoplasma
dna
observ
european
pharmacopoeia
method
publish
european
pharmacopeia
method
indirect
dna
stain
cultur
supernat
provid
result
within
h
compar
favour
week
detect
cultur
howev
method
sensit
much
reduc
cfuml
may
improv
cocultur
test
cell
line
presenc
indic
cell
line
vero
provid
surfac
adher
grow
mycoplasma
enrich
step
result
sensit
cfuml
pcr
technolog
also
adapt
detect
mycoplasma
cell
cultur
method
combin
number
advantag
render
competit
reliabl
method
pcr
sensit
specif
rapid
procedur
detect
defin
dna
sequenc
amplif
target
dna
sequenc
visual
fragment
ethidium
bromid
stain
gel
simultan
real
time
pcr
anoth
import
advantag
pcr
technolog
simplic
establish
use
routin
cell
culturist
cell
cultur
molecular
biolog
laboratori
without
train
classic
mycoplasma
detect
toji
et
al
hand
method
affect
inhibitor
might
introduc
cell
cultur
media
due
rapid
prepar
procedur
use
eg
supernat
denatur
boil
raw
cell
lysat
treat
proteinas
k
instead
purifi
dna
bacteri
contamin
pcr
reagent
lead
amplif
obvious
back
cell
cultur
contamin
razin
especi
nest
pcr
method
test
mycoplasma
use
antibiot
cell
cultur
minim
cell
cultur
without
antibiot
sever
passag
least
week
allow
mycoplasma
grow
detect
amount
region
genom
conserv
use
target
primer
detect
speci
one
oftenchosen
conserv
region
amplif
rrna
code
region
stacey
use
region
advantag
mani
copi
eg
copi
avail
could
revers
transcrib
dna
high
copi
number
increas
sensit
pcr
method
barri
et
al
method
use
principl
nucleic
acid
hybrid
ribosom
rna
rrna
detect
weisburg
et
al
possibl
detect
posit
sampl
min
mycoplasma
tissu
cultur
mtc
nonisotop
ni
kit
use
allbacteri
probe
detect
speci
mycoplasma
acholeplasma
commonli
infect
cell
cultur
kit
use
singlestrand
dna
probe
dna
chemiluminesc
label
complementari
rrna
target
microorgan
likewis
stabl
dnarna
hybrid
measur
genprob
luminomet
nelson
et
al
form
posit
result
luminomet
read
equal
greater
cutoff
valu
express
rel
light
unit
method
test
wide
rang
speci
mycoplasma
acholeplasma
spiroplasma
ureaplasma
method
adequ
respect
detect
howev
sensit
detect
low
eg
addit
mycoplasma
numer
type
microorgan
may
contamin
persist
cell
cultur
go
undetect
without
specif
isol
method
case
member
mycobacterium
genu
bacteria
demand
nutrit
requir
isol
microorgan
differ
cultur
condit
requir
detect
possibl
cover
type
potenti
contamin
nevertheless
wise
remain
awar
potenti
rare
contamin
type
prepar
attempt
isol
organ
unusu
observ
aris
could
explain
contamin
routin
clean
cell
cultur
best
restrict
use
antibiot
primari
cell
cultur
event
cell
cultur
becom
contamin
bacteria
yeast
fungi
mycoplasma
best
cours
action
discard
cultur
check
cell
cultur
reagent
contamin
use
well
disinfect
microbiolog
safeti
cabinet
work
surfac
resuscit
new
ampoul
cell
frozen
stock
case
contamin
sporeform
microorgan
advis
fumig
work
area
facil
howev
case
irreplac
stock
treatment
antimicrobi
may
necessari
elimin
contamin
although
must
acknowledg
attempt
rare
success
case
cell
cultiv
presenc
antibiot
day
passag
perform
highest
dilut
cell
growth
possibl
contamin
still
detect
period
time
unlik
antimicrobi
use
prove
success
anoth
antibiot
tri
possibl
check
contamin
carri
treatment
eg
day
treatment
case
bacteria
fungi
approxim
day
treatment
mycoplasmacontamin
line
antibiot
chosen
elimin
contamin
depend
sensit
microorgan
question
perform
test
determin
speci
organ
minimum
inhibitori
concentr
mic
antibiot
use
promot
erad
import
rememb
cell
may
suscept
antibiot
toxic
effect
thu
select
mic
level
avoid
use
excess
concentr
doyl
griffith
virus
introduc
final
product
sever
rout
includ
use
contamin
biolog
reagent
anim
serum
compon
use
viru
induct
express
specif
gene
encod
desir
protein
use
contamin
reagent
monoclon
antibodi
use
contamin
excipi
eg
cryoprotect
formul
use
murin
human
feeder
embryon
stem
cell
cultur
contamin
cell
medium
handl
common
supplement
cell
cultur
bovin
serum
new
guidelin
describ
screen
bovin
serum
use
manufactur
human
biolog
product
recent
introduc
european
medicin
evalu
agenc
guidelin
design
qualiti
control
safeti
bovin
serum
use
manufactur
human
biolog
medicin
product
serum
contain
detect
bacteria
fungi
mycoplasma
viru
test
list
includ
known
bovin
pathogen
includ
bovin
viral
diarrhoea
viru
bvdv
bovin
polyomaviru
bovin
parvoviru
bovin
adenoviru
blue
tongu
viru
rabi
viru
bovin
respiratori
syncyti
viru
reoviru
serum
sourc
countri
virus
present
low
incid
contamin
cell
line
bvdv
may
caus
slight
chang
growth
rate
sinc
viru
noncytopath
macroscop
microscop
chang
cultur
detect
immunoperoxidas
prefer
use
semiquantit
rtpcr
intern
control
allow
quantif
number
detect
bvdv
rna
molecul
sampl
detect
bvdv
allow
discrimin
background
signal
real
bvdv
contamin
rijsewijk
et
al
embryon
stem
cell
line
deriv
mous
feeder
deriv
human
feeder
transmit
infecti
microorgan
recipi
evid
certain
mous
virus
like
hantaan
viru
reoviru
type
sendai
viru
lactic
dehydrogenas
viru
lymphocit
choriomening
viru
capabl
infect
human
primat
european
medicin
evalu
agenc
furthermor
virus
like
ectromelia
viru
minut
viru
mice
mous
adenoviru
mous
cytomegaloviru
mous
rotaviru
pneumonia
viru
mice
toolan
viru
kilham
rat
viru
capabl
repli
vitro
cell
human
primat
origin
although
infect
capac
shown
date
european
medicin
evalu
agenc
event
use
feeder
cell
human
origin
numer
virus
infecti
agent
suscept
transmit
recipi
see
control
donor
cell
deriv
stem
cell
line
futur
technolog
base
use
hybrid
chip
use
microarray
immobil
oligonucleotid
provid
rapid
use
methodolog
identif
contamin
laassri
et
al
microchip
contain
severalbaseslong
oligonucleotid
probe
specif
viru
speci
ensur
redund
robust
assay
region
approxim
base
long
amplifi
sampl
viral
dna
fluoresc
label
deoxynucleotid
triphosph
dntp
singlestrand
dna
prepar
strand
separ
hybrid
carri
plastic
coverslip
result
fluoresc
pattern
quantifi
use
confoc
laser
scanner
laassri
et
al
howev
techniqu
need
care
valid
sensit
specif
appli
safeti
test
human
tissu
product
stem
cell
line
therapi
european
regulatori
agenc
european
medicin
evalu
agenc
identifi
need
risk
assess
tse
product
deriv
rumin
human
be
expos
secondari
infect
tsecjd
use
medic
procedur
administ
biolog
product
deriv
human
includ
blood
llewelyn
et
al
peden
et
al
result
prevent
measur
implement
respect
blood
product
cell
tissu
graft
decontamin
surgic
instrument
diagnosi
case
carri
mean
detect
resist
prionic
protein
prpre
differ
method
chemiluminesc
immunoassay
sandwich
western
blot
enzymelink
immunosorb
assay
elisa
sandwich
pcr
although
specif
diagnost
method
nearli
ironsid
lee
et
al
wadsworth
et
al
sensit
inadequ
assur
valu
neg
result
altern
method
would
consist
use
transgen
mice
would
vaccin
tissu
fluid
unknown
infect
cell
line
use
bovin
serum
obtain
good
practic
stem
cell
bank
whether
research
therapi
carri
routin
environment
monitor
laboratori
cell
cultur
product
prepar
class
ii
microbiolog
safeti
cabinet
review
everi
month
assur
carri
function
protect
product
oper
effect
varieti
method
detect
monitor
environment
air
qualiti
contamin
includ
use
devic
settl
plate
contact
plate
swab
ec
guid
good
manufactur
practic
european
pharmacopoeia
b
settl
plate
effect
use
studi
differ
point
throughout
laboratori
identifi
foci
contamin
risk
plate
open
approxim
h
time
cover
incub
h
parenter
societi
end
period
plate
examin
rule
presenc
microorgan
growth
obtain
environment
monitor
data
relat
iso
air
qualiti
standard
eg
intern
organ
standard
air
sampl
system
use
contact
plate
attatch
system
sampl
larg
air
volum
provid
greater
reliabl
respect
microbi
charg
point
laboratori
space
environment
monitor
activ
laboratori
includ
test
sampl
work
surfac
wall
equip
instrument
use
convex
cultur
plate
swab
case
latter
use
sampl
laboratori
introduc
liquid
medium
like
thioglycol
broth
trypton
soya
agar
broth
cultur
subcultur
onto
agar
plate
certain
level
contamin
accept
limit
defin
term
warn
level
action
level
depend
critic
work
area
level
cleanli
reach
normal
oper
condit
cell
bank
stem
cell
line
aris
necess
guarante
exist
appropri
sourc
cell
line
standardis
way
develop
therapi
clinic
trial
addit
provid
reliabl
reproduc
sourc
cell
advantag
system
accredit
cell
bank
includ
assur
safe
start
materi
use
clinic
trial
also
check
authent
stabil
perform
potenti
sourc
microbi
contamin
includ
cell
line
reagent
laboratori
environ
breakdown
asept
process
avail
good
qualiti
cell
reagent
qualifi
sourc
necessari
guarante
qualiti
product
process
final
product
cell
stock
cell
product
routin
screen
regim
help
earli
detect
contamin
sinc
type
manipul
potenti
sourc
contamin
valid
qualiti
control
safeti
test
method
vital
assur
qualiti
test
data
also
reduc
need
repeat
test
procedur
carri
document
accord
applic
nation
requir
intern
standard
materi
may
transfer
across
border
although
rigor
test
perform
seriou
human
pathogen
test
perform
detect
human
anim
virus
desir
stem
cell
line
use
human
therapi
case
agent
may
low
undetermin
pathogen
may
affect
decis
use
cell
therapi
howev
use
stem
cell
line
possibl
agent
multipli
unaccept
level
must
monitor
safe
practic
laboratori
base
fundament
norm
includ
good
microbiolog
practic
safe
manipul
microorgan
may
aris
tissu
cell
oper
basic
knowledg
microbiolog
well
knowledg
cultiv
pathogen
likewis
basic
knowledg
techniqu
disinfect
work
surfac
equip
environ
awar
need
minim
product
aerosol
control
potenti
mechan
spread
contamin
tissu
worker
assur
qualiti
cell
line
requir
authent
characteris
accur
descript
proven
confirm
absenc
contamin
aim
import
stem
cell
line
research
clinic
use
appropri
document
provid
recipi
cell
line
product
deriv
stem
cell
line
cell
therapi
regen
medicin
provid
new
solut
seriou
diseas
injuri
still
mani
problem
solv
final
routin
applic
human
realis
sensit
diagnost
test
provid
complet
biosafeti
product
necessari
also
vital
appli
improv
detect
technolog
maintain
vigil
new
potenti
agent
affect
biosafeti
stem
cell
line
